Salt Selection in Drug Development - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Salt Selection in Drug Development
The selection of an appropriate salt form for a potential drug candidate is an opportunity to modulate its characteristics to improve bioavailability, stability, manufacturability, and patient compliance.

Pharmaceutical Technology
Volume 3, Issue 32

24. R. Hilfiker, F. Blatter, and M.V. Raumer, "Relevance of Solid-State Properties for Pharmaceutical Products," in Polymorphism in the Pharmaceutical Industry, R. Hilfiker, Ed. (Wiley–VCH, Weinheim, Germany, 2006), pp. 1–19.

25. S. Balbach and C. Korn, "Pharmaceutical Evaluation of Early Development Candidates—the 100-mg Approach," Int. J. Pharm. 275 (1–2), 1–12 (2004).

26. G. Davies, "Changing the Salt, Changing the Drug," Pharm. J. 266 (7138), 322–323 (2001).

27. J.D. Higgins and W.L. Rocco, "Pharma Preformulation: A Stop Along the Drug Development Highway," Today's Chemist at Work 12 (7), 22–26 (2003).

28. A.T.M. Serajuddin et al., "Preformulation Study of a Poorly Water Soluble Drug α-pentyl-3-(2-quinolinylmethoxy) benzenemethanol: Selection of the Base for Dosage Form Design," J. Pharm. Sci. 75 (5), 492–496 (1986).

29. R.J. Bastin, M.J. Bowker, and B.J. Slater, "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities," Org. Proc. Res. Dev. 4 (5), 427–435 (2000).

30. "Orinase Diagnostic-Product Information,", accessed Jan. 21, 2006.

31. R.M. Everett et al., "Nephrotoxicity of Pravadoline Maleate (WIN 48098-6) in Dogs: Evidence of Maleic Acid-Induced Acute Tubular Necrosis," Fundam. Appl. Toxicol. 21 (1), 59–65 (1993).

32. D. J. Snodin, "Residues of Genotoxic Alkyl Mesylates in Mesylate Salt Drug Substances: Real or Imaginary Problems?," Regul.Toxicol. Pharmacol. 45 (1), 79–90 (2006).

33. A. Allerman, "New Drug Watch,", accessed Dec. 15, 2006.

34. W.Q. Tong and G. Whitesell, "In situ Salt Screening—A Useful Technique for Discovery Support and Preformulation Studies," Pharm. Dev. Technol. 3 (2), 215–223 (1998).

35. C.R. Gardner et al., "Application of High Throughput Technologies to Drug Substance and Drug Product Development," Comput. Chem. Eng. 28 (6–7), 943–953 (2004).

36. A.W. Newman and G.P. Stahly, "Form Selection of Pharmaceutical Compounds," in Handbook of Pharmaceutical Analysis, vol. 117, L. Ohannesian and A.J. Streeter, Eds. (Marcel Dekker, New York, 2002), pp. 1–58.

37. G.L. Engel et al., "Salt Form Selection and Characterization of LY333531 Mesylate Monohydrate," Int. J. Pharm. 198 (2), 239–247 (2000).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here